Alcon is making an aggressive return to the minimally invasive glaucoma surgery market by acquiring Ivantis for at least $475m, the companies announced on 8 November.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?